The Association Between Hypothyroidism and Cognitive Function Change in Women across the Menopause Transition: The Study of Women's Health Across the Nation.

IF 5.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Thyroid Pub Date : 2024-10-01 Epub Date: 2024-09-18 DOI:10.1089/thy.2024.0358
Matthew D Ettleson, Kelly Karavolos, Sherri-Ann M Burnett-Bowie, Lynda H Powell, Imke Janssen
{"title":"The Association Between Hypothyroidism and Cognitive Function Change in Women across the Menopause Transition: The Study of Women's Health Across the Nation.","authors":"Matthew D Ettleson, Kelly Karavolos, Sherri-Ann M Burnett-Bowie, Lynda H Powell, Imke Janssen","doi":"10.1089/thy.2024.0358","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Patients treated for hypothyroidism with levothyroxine (LT4) monotherapy may present with persistent hypothyroidism symptoms, including cognitive symptoms, despite having a normal thyroid stimulating hormone (TSH) level. It remains unclear whether LT4 monotherapy is sufficient to normalize cognitive function outcomes over time. <b><i>Methods:</i></b> This is a multisite longitudinal study of a diverse group of women during midlife representing 5 ethnic/racial groups from 7 enrollment sites across the United States in the Study of Women's Health Across the Nation. Women were screened for a history of thyroid disease and the use of LT4. The study consisted of two primary groups: women with LT4-treated hypothyroidism and control women without thyroid disease. Each participant completed up to 9 cognitive assessments over the study period testing processing speed, working memory, and episodic memory (immediate and delayed recall). Multivariable generalized linear mixed models of scores for each cognitive assessment were developed to determine the association between LT4-treated hypothyroidism and cognitive function trajectories. Covariates included sociodemographic, clinical characteristics, and menopausal status (pre/early peri, late peri, and surgical/post). Sensitivity analyses were conducted to assess the impact of abnormal TSH levels and practice effects (i.e., improvements in scoring after repeated testing). <b><i>Results:</i></b> Of the 2033 women who were included in the study, 227 (11.2%) met criteria for LT4-treated hypothyroidism. At baseline, both processing speed and working memory scores were higher in LT4-treated women (mean processing speed scores: 56.5 vs 54.4; <i>p</i> value = 0.006; mean working memory scores: 6.8 vs 6.4; <i>p</i> value = 0.018). However, when considering the effect of LT4-treated hypothyroidism over time, there were no significant differences in the rate of cognitive decline (in any measure) between the hypothyroidism and control groups with or without covariate adjustment. The results were similar when considering LT4-treated women with abnormal TSH levels or after minimizing practice effects. <b><i>Conclusions:</i></b> We observed no difference in cognitive decline between women with LT4-treated hypothyroidism and women without thyroid disease. For similar aged patients with cognitive complaints, if thyroid function testing is normal, clinicians should consider causes other than inadequate thyroid hormone treatment to explain these symptoms.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"1205-1213"},"PeriodicalIF":5.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2024.0358","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients treated for hypothyroidism with levothyroxine (LT4) monotherapy may present with persistent hypothyroidism symptoms, including cognitive symptoms, despite having a normal thyroid stimulating hormone (TSH) level. It remains unclear whether LT4 monotherapy is sufficient to normalize cognitive function outcomes over time. Methods: This is a multisite longitudinal study of a diverse group of women during midlife representing 5 ethnic/racial groups from 7 enrollment sites across the United States in the Study of Women's Health Across the Nation. Women were screened for a history of thyroid disease and the use of LT4. The study consisted of two primary groups: women with LT4-treated hypothyroidism and control women without thyroid disease. Each participant completed up to 9 cognitive assessments over the study period testing processing speed, working memory, and episodic memory (immediate and delayed recall). Multivariable generalized linear mixed models of scores for each cognitive assessment were developed to determine the association between LT4-treated hypothyroidism and cognitive function trajectories. Covariates included sociodemographic, clinical characteristics, and menopausal status (pre/early peri, late peri, and surgical/post). Sensitivity analyses were conducted to assess the impact of abnormal TSH levels and practice effects (i.e., improvements in scoring after repeated testing). Results: Of the 2033 women who were included in the study, 227 (11.2%) met criteria for LT4-treated hypothyroidism. At baseline, both processing speed and working memory scores were higher in LT4-treated women (mean processing speed scores: 56.5 vs 54.4; p value = 0.006; mean working memory scores: 6.8 vs 6.4; p value = 0.018). However, when considering the effect of LT4-treated hypothyroidism over time, there were no significant differences in the rate of cognitive decline (in any measure) between the hypothyroidism and control groups with or without covariate adjustment. The results were similar when considering LT4-treated women with abnormal TSH levels or after minimizing practice effects. Conclusions: We observed no difference in cognitive decline between women with LT4-treated hypothyroidism and women without thyroid disease. For similar aged patients with cognitive complaints, if thyroid function testing is normal, clinicians should consider causes other than inadequate thyroid hormone treatment to explain these symptoms.

更年期妇女甲状腺机能减退与认知功能变化之间的关系:全国妇女健康研究(SWAN)。
背景 接受左甲状腺素(LT4)单药治疗的甲状腺功能减退症患者尽管促甲状腺激素(TSH)水平正常,但可能会出现包括认知症状在内的持续性甲状腺功能减退症症状。LT4单药治疗是否足以使认知功能随时间恢复正常,目前仍不清楚。方法 这是一项多地点纵向研究,研究对象是美国全国妇女健康研究(SWAN)的 7 个注册地点中代表 5 个民族/种族的中年女性群体。研究人员对妇女进行了甲状腺疾病史和LT4使用情况的筛查。研究包括两个主要群体:接受过LT4治疗的甲状腺功能减退症妇女和未患甲状腺疾病的对照组妇女。每位参与者在研究期间最多完成 9 次认知评估,测试处理速度、工作记忆和外显记忆(即时和延迟回忆)。研究人员对每项认知评估的得分建立了多变量广义线性混合模型,以确定经LT4治疗的甲状腺功能减退症与认知功能轨迹之间的关联。协变量包括社会人口学特征、临床特征和绝经状态(围绝经期前/早期、围绝经期晚期和手术后/绝经期)。进行了敏感性分析,以评估促甲状腺激素水平异常和实践效应(即重复测试后评分提高)的影响。结果 在参与研究的 2033 名女性中,有 227 人(11.2%)符合经 LT4 治疗的甲状腺功能减退症的标准。在基线时,接受过LT4治疗的女性的处理速度和工作记忆得分都更高(处理速度平均得分:56.5 vs 54.4;工作记忆平均得分:56.5 vs 54.4):平均处理速度得分:56.5 vs 54.4;p 值 = 0.006;平均工作记忆得分:6.8 vs 6.4;p 值 = 0.007:6.8 vs 6.4;p 值 = 0.018)。然而,在考虑LT4治疗甲减的长期效果时,无论是否进行协变量调整,甲减组和对照组的认知能力下降率(在任何指标上)都没有显著差异。如果考虑到接受过LT4治疗且TSH水平异常的女性,或在尽量减少实践效应后,结果也相似。结论 我们观察到,接受过LT4治疗的甲状腺功能减退症女性患者与未患甲状腺疾病的女性患者在认知能力下降方面没有差异。对于有认知障碍的同龄患者,如果甲状腺功能检测正常,临床医生应考虑甲状腺激素治疗不当以外的原因来解释这些症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信